Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Overview of attention for article published in BMC Medicine, August 2022

Altmetric Badge

Mentioned by

twitter: 2 tweeters

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 10 Mendeley

Summary Twitter Dimensions citations

So far, Altmetric has seen 2 tweets from 2 users, with an upper bound of 10,167 followers.

New #clinical #cancer #research - https://t.co/pnWQz6L9Uy #Pyrotinib combined with #apatinib for targeting metastatic non-small cell #lungcancer with #HER2 alterations: a prospective, open-label, single-arm phase 2 study #PATHER2 https://t.co/Rsl8493WWO

Reply Retweet Favourite

New article: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2) https://t.co/gyuaw35AYq #lungcancer #oncology https://t.co/HRoQOTEpTn

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity.